<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The differentiation inhibitory factor nm23 can inhibit the differentiation of murine and human myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>We recently reported that nm23 genes were overexpressed in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and a higher level of nm23-H1 expression was correlated with a poor prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, especially in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M5 (<z:hpo ids='HP_0004845'>acute monocytic leukemia</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the importance of nm23 expression as a prognostic factor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, we compared it with other putative prognostic factors in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>An analysis of the correlation between nm23 expression and the clinical parameters of 110 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> demonstrated that increased nm23-H1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were associated with resistance to initial chemotherapy and with reduced overall survival </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate analysis using Cox's proportional hazard model also showed that elevated nm23-H1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels significantly contributed to the prognosis of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Especially in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M5, nm23-H1 status was the most important prognostic factor </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, to determine whether we can apply the results observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> to other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, we investigated the relative levels of nm23-H1 and nm23-H2 transcripts in 149 patients with hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, including 110 with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 9 with de novo <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 14 with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 16 with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), and 5 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects by the reverse transcriptase-polymerase chain reaction </plain></SENT>
<SENT sid="7" pm="."><plain>Expression of nm23-H1 was significantly higher in <z:hpo ids='HP_0000001'>all</z:hpo> the hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, except <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, than in <z:mpath ids='MPATH_458'>normal</z:mpath> blood cells </plain></SENT>
<SENT sid="8" pm="."><plain>nm23 may have a prognostic effect in these <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> as well as in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>